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Summary
Background: The aim of the study was to assess the effectiveness of treatment with pegylated interferon-α2a (PegIFN-α2a)
PEGASYS® ROCHE at 180 µg dose administered 1 × week in combination with ribavirin (RBV) COPEGUS® at 800 mg/d dose
administered every day for 48 weeks to patients with chronic hepatitis C within the framework of an open-label, non-randomized clini-
cal study.
Material and Methods: The study was carried out in a group of 190 adult patients of both sexes, among them 167 had undergone
liver biopsies. The treatment was completed by 181 subjects. In addition to standard biochemical tests, HCV-RNA, genotype and
viremia level were determined. Control tests were carried out after 6 months of the end of treatment to assess sustained virological
response (SVR).
Results: SVR was obtained in 58.2% of patients, without statistically significant difference between men and women; there was a
difference between the group of patients over 50 years of age as compared with those below that age (43.2% vs. 62.4%, respectively;
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BACKGROUND
The treatment of chronic hepatitis C has been the subject
of intensive clinical studies during the recent years. They
have resulted in increasing rates of sustained virological
response (SVR). The effects of combined treatment with
interferon-α (IFN-α) and ribavirin (RBV) have been espe-
cially promising [1]. It has been demonstrated, also in mul-
ticenter studies carried out in Poland [2], that after com-
bined IFNα2b + RBV therapy, continued for 6 months,
with efficacy assessment after the same time, SVR was
obtained in 37% of patients. Marked improvement of ther-
apeutic success rates was obtained after the introduction of
combined therapy using pegylated interferons with poly-
ethylene glycol of various molecular weight incorporated
in the drug molecule. The pegylated interferon prepara-
tions include: PegIFN-α2b (12 kD m.w.; Schering-Plough)
and PegIFN-α2a (40 kD m.w.; Roche). Such pharmacolog-
ical formula prolongs the time of IFN-α activity and
reduces the dosing frequency from three to one injection a
week [review: 3]. 48-week treatment with Peg-IFNα and
RBV has almost doubled the SVR rates, which ranged in
international multicenter studies from 54% to 63% [4–6],
and reached very high levels in patients infected with
non-1 genotype – from 76% to 80% [4–6]. The presented
paper is a study stage summary report concerning the
effectiveness of combined PegIFN-α2a plus RBV therapy
carried out in Polish clinical centers. It takes into consider-
ation the SVR analysis related to HCV genotype, viremia
level and extent of liver fibrosis, as well as other parame-
ters. As the data concerning larger numbers of patients
become available, the next report will be prepared.
MATERIAL AND METHODS
Recruitment of patients to the study was based on the
following diagnostic criteria for chronic viral hepatitis C:
1) At least 6 months from the moment of anti-HCV
detection.
2) HCV-RNA positivity in the serum.
3) Elevated alanine aminotransferase (AlAT) activity.
4) In liver biopsy: signs of chronic hepatitis C.
The above criteria were met by 190 patients of mean
age 41±12 (18–69) years, including 64 females: mean
age 42±10 (21–69) years and 126 males: mean age
40±13 (18–65) years. Table 1 presents comprehensive
characteristics of the patients included in the study.
In all the patients, on day: ‘0’ (before inclusion in the
study), and then in weeks 2-4-8-16-24-32-40-48 during
the therapy and 24 weeks after its completion (week 72)
the following laboratory parameters were determined:
• AlAT, AspAT and alkaline phosphatase activity;
• hemoglobin, bilirubin, albumin, creatinine, uric acid
and triglyceride levels;
• erythrocyte, platelet, leukocyte and neutrophil counts;
• TSH.
Among the aforementioned parameters, AlAT activity,
hemoglobin level and platelet, leukocyte and neutrophil
counts were selected for further analysis.
HCV-RNA was determined using a COBAS AMPLICOR
HCV Test v. 2.0 system of over 50 IU/ml sensitivity in
the qualitative method, whereas a COBAS AMPLICOR
p= 0.040). Higher SVR rates (p=0.001) were observed in patients infected with non-1 HCV genotype in comparison with
genotype 1 (85.7% vs. 52.8%). In patients with genotype 1 and viremia equal to, or lower than 800 000 lU/ml SVR was 61.3%
while in patients with viremia greater than 800.000 IU/ml SVR was 41.9% (p=0.028). Such difference was not found for non-1
genotype patients. No significant differences in SVR values related to the stage of fibrosis were observed (patients with stage 1 and 2
according to 0–4 staging scale predominated: 73.6%). Higher SVR rates (p=0.034) were obtained in patients receiving ribavirin
doses above 10.6 mg/kg b.w. (67.6% and 50%, respectively) without statistically significant difference between the patients treated
with interferon and ribavirin doses, considered both jointly and separately, above and below 80% of the scheduled dose. Hemoglobin
level, leukocyte and neutrophil counts decreased significantly during the therapy and returned to the reference values after its comple-
tion. There was a statistically significant decrease of AIAT activity during the treatment, both in patients with and without SVR,
which was observed also 6 months after its completion. The treatment was not completed by 9 patients (5 because of adverse effects,
and 4 for subjective reasons).
Conclusions: 1. The overall effectiveness of treatment, assessed 6 months after its completion, reached 58.2%, without taking into
consideration HCV genotype and viremia level. 2. Patients infected with non-1 genotype responded significantly better than those with
genotype 1 (85.7% vs. 52.8%). 3. Patients infected with genotype 1 with low viremia levels responded significantly better than those
with genotype 1 and high viremia (61.3% vs. 41.9%). 4. The response to treatment was significantly better in patients below 50 years
of age. 5. No significant differences in response were found with respect to: sex, previous antiviral treatment and the stage of fibrosis.
6. Patients treated with ribavirin doses ≥10.6 mg/kg responded significantly better than those receiving doses <10.6 mg/kg.
Key words: chronic hepatitis C • combined pegylated interferon-α (IFN-α) and ribavirin (RBV) therapy •
sustained virological response related to HCV genotype
Patients included in the study
Age
Females
Males
Mean age – females
Mean age – males
Previous treatment
No previous treatment
Body weight
n=190
41 yrs ± 12 (18–69 yrs)
n=64; (33.6%)
n=126; (66.3%)
42±10, (21–69 yrs)
40±13, (18–65 yrs)
n=59; (31.1%)
n=131; (68.9%)
n=178;76 kg ± 14 (41–126 kg)
Table 1. Characteristics of patients included in the study.
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HCV MONITOR Test v.1.5 system of 600–500 thousand
IU/ml linearity was used for quantitative determinations.
For HCV-RNA genotyping, a Versant HCV Genotype
LiPA Assay system was used.
Quantitative and qualitative HCV-RNA determinations
were performed before the commencement of treat-
ment, immediately after its completion (end of the treat-
ment response, ETR) and 24 weeks after its completion in
order to determine sustained response to the therapy
(sustained virological response, SVR).
Liver biopsies were performed with standard Menghini
method. Various scales were used for histopathologic
assessment, separate ones for inflammation (G, ‘grading‘)
and fibrosis (S, ‘staging‘). Because of their different charac-
ter, the final analysis was carried out on the selected
results obtained using a uniform 5-point (0–4) scale
(according to 7), separately for hepatitis and fibrosis (G
and S: 0–4 scores). However, because of a smaller number
of obtained results concerning inflammation (G), as com-
pared with fibrosis (S), the former parameter was not
taken into account in the final analysis. The reduced num-
ber of data concerning hepatitis assessment resulted from
the use of more complex assessment scales by some cen-
ters, which could not be converted into the 5-point scale.
Laboratory tests were performed according to the pro-
cedure which was unified in all the study centers.
The following tests were applied in statistical analyses:
Fisher, McNemara, Wilcoxon and t-Student for related
samples. The SPSS v. 8.0.1 statistical software package
was used.
The in tractu and final assessed parameters included:
• in tractu: adverse effects (discussed in a separate publi-
cation);
• final: HCV-RNA undetectability in week 24 after the
completion of treatment (SVR).
Pegylated interferon-α2a (PegIFN-α2a) PEGASYS® RO-
CHE at 180 µg once a week with ribavirin (RBV) COPE-
GUS at 800 mg/d dose were used. The drugs were
administered for 48 weeks with dose modifications de-
pendent on tolerability.
RESULTS
The treatment was completed by 181 patients and dis-
continued by 9. The reasons for discontinuation are listed
in Table 2.
The availability of results varied with respect to differ-
ent tests, and the numbers of patients taken into
account in the final analysis are presented in Table 3.
Unless another reason for the differences in numbers is
stated in the discussion, they were caused by the lack of
complete data in the database where the in tractu results
were collected. With respect to some information, the
reasons for differences will be specified, whereas the
remaining ones for a specific parameter will result from
the circumstances presented above.
Genotyping results in all patients included in the study
(n=190) are presented in Figure 1, whereas those obta-
ined in 170 patients who completed the treatment and
their HCV-RNA results from week 24 after treatment
were available – in Figure 2.
As it follows from the comparison of these two values,
patients with genotype 1 were predominant (83.2% vs.
Neutropenia 2 p. (410–680/mm3) (week 40 and 41)
Thrombocytopenia 1 p. (32 thousand/mm3) (week 30)
Suspicion of follicular carcinoma 1 p.(week 42)
Hyperthyroidism 1 p. (week 22)
Refusal to continue the therapy 3 p. (week 2, 20 and 29)
General poor tolerance (repeated syncopes) 1p. (week 30)
Table 2. Reasons for discontinuation of treatment.
HCV RNA availability in week 72
Liver biopsy 
HCV RNA in week 72 + biopsy
ALT values + HCV RNA in week 72
Hb values + HCV RNA in week 72
Platelets + HCV RNA in week 72
Leukocytes + HCV RNA in week 72
Neutrophils + HCV RNA in week 72
n=170
n=167
n=148
n=146
n=150
n=145
n=149
n=136
Table 3. Material: data availability.
HCV RNA: genotypes 
Genotypes
(n=190)
Genotype 1
n=158 (83.2%)
Genotype non-1
n=32 (16.8%)
1a-13 
(6.8%)
1b-145 
(76.3%)
3a-29 
(15.3%)
4c 4d-2
(1.1%)
1b/4-1 
(0.5%)
Figure 1. HCV RNA: genotypes.
Figure 2. HCV RNA: genotypes.
HCV RNA: genotypes 
1
Genotypes
(n=170)
Genotype 1
142 (83.5%)
Genotyp nom-1
28 (16.5%)
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83.5%) and patients with non-1 genotypes constituted a
minority (16.8% vs. 16.5%). Among those infected with
genotype 1, genotype 1b was the most frequent (76.3%),
whereas among non-1 genotype infections genotype 3a
predominated (15.3%).
Viremia levels were divided into two categories: over 800
thousand IU/mL (high viremia, HV) and equal to, or
below 800 thousand IU/mL (low viremia, LV). For the
whole population of 190 subjects, HV was found in 89/190
(46.8%) and LV in 101/190 (53.2%). If, the viremia values
were calculated for genotype 1 (n=158) and separately for
non-1 (n=32), in the genotype 1 subgroup HV accounted
for 74/158 (46.8%), and LV for 84/158 (53.2%), and in the
non-1 genotype subgroup for 15/32 (46.9%) and 17/32
(53.1%), respectively. As 170 patients were included in the
final analysis, calculations analogous to the above demon-
strated: HV 76/170 (44.7%) and LV - 94/170 (55.3%). If
the viremia values were calculated for genotype 1 (n=142)
and separately for non-1 (n=28), in the genotype 1 sub-
group HV accounted for 62/142 (43.7%), and LV for
80/142 (56.3%), and in the non-1 genotype subgroup for
14/28 i.e. 50.0%, respectively. The decreased number of
analyzed subjects by 20, from 190 to 170 (by 10.5%) did
not affect the representativeness of the analyzed parame-
ter in the final assessment.
Among 190 patients, 4 had no liver biopsies performed
before the institution of treatment because of hemophilia.
In the whole material of pre-treatment biopsies, with the
relevant data available in the database (n=167), patients
with stage 1 (36.5%) and 2 (38.3%) fibrosis, collectively
accounting for 74.8% of hepatic lesions, were predomi-
nant, whereas in 7.2% of cases stage 0 was found, in
11.4 % – stage 3 and in 6.6% – stage 4. Among the patients
who completed the treatment and whose liver biopsy
results were available, it was possible to determine SVR in
148/167 (88.6%) patients, in whom pre-therapy liver biop-
tate assessments according to the 0–4 fibrosis staging scale
were performed. The decrease of the number of analyzed
data by 19 did not affect the proportions of fibrosis stage-
related distribution in the particular subgroups, which
results from the comparison of percentage values
obtained for 167 initially analyzed patients and 148 ones
subjected to the final assessment. Patients with stage 1 and
2 fibrosis were still predominant (35.8% and 37.8%,
respectively, collectively – 73.6%). No signs of fibrosis were
found in 11 (7.4%) and the same number had advanced
stage fibrosis (S4).
The results of selected biochemical tests are presented
in Table 4 and in Figures 3–7.
The dynamics of changes was as follows:
1)AlAT activity decrease was statistically significant
(p<0.001) on all terms of tests carried out during the
therapy and remained at that level for 24 weeks after its
AlAT
(IU/ml)
Hb
(g/dl)
Platelets
(×109/L)
Leukocytes
(×109/L)
Neutrophils
(×109/L)
n=146
n=150
n=145
n=149
n=136
114±72.4
(102.1–125.8)
14.8±1.4
(14.6–15.1)
199.8±54.5
(190.9–208.8)
6.1±1.3
(5.9–6.3)
3.2±0.9
(3.0–3.3)
71.2±43.9
(64.–78.4)
14.1±1.5
(13.8–14.3)
161.0±49.0
(153.0–169.1)
4.3±1.4
(4.0–4.5)
1.9±0.8
(1.7–2.0)
55.0±31.4
(49.8–60.1)
12.9±1.5
(12.6–13.1)
138.6±46.6
(130.9–146.2)
3.4±1.3
(3.2–3.6)
1.5±0.7
(1.4–1.6)
43.8±37.7
(37.7–50)
12.5±1.4
(12.2–12.7)
142.7±46.7
(135.0–150.4)
3.2±1.1
(3.0–3.4)
1.6±0.8
(1.5–1.7)
45.2±38.5
(38.9–51.5)
12.6±1.3
(12.4–12.8)
139.0±46.2
(131.4–146.6)
3.2±1.0
(3.0–3.4)
1.7±0.7
(1.5–1.8)
47.7±48.4
(39.8–55.7)
12.6±1.4
(12.4–12.9)
136.8±45.6
(129.3–144.3)
3.1±1.2
(3.0–3.3)
1.7±0.9
(1.5–1.8)
50.0±55.6
(40.9–59.1)
14.7±1.6
(14.4–15.0)
199.5±55.2
(190.4–208.5)
5.8±1.6
(5.6–6.1)
3.3±1.2
(3.1–3.5)
Table 4. Results of laboratory tests (x±SD; 95% confidence intervals).
Parameter n
0 2 8 24 32 48 72
Treatment week
Figure 3. Mean values for ALAT.
Figure 4. Mean values for hemoglobin.
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completion. This applied both to patients who had
attained SVR as well as those with detectable HCV-RNA
six months after termination of treatment.
2)Hemoglobin level, as well as platelet, leukocyte and
neutrophil counts decreased significantly during the
therapy (p<0.001) and increased to the values reach-
ing no statistical significance in comparison with the
baseline (‘0’ time).
It was possible to assess SVR in 170 cases. Among those, 99
(58.2%) demonstrated undetectable levels of HCV-RNA 6
months after the completion of the therapy. The analyzed
group consisted of 58 women, 39 of whom obtained SVR
(67.2%) and 112 men with SVR obtained in 60 (53.6%).
The sex-related SVR frequencies reached no statistical sig-
nificance (p>0.05). All the patients were divided into two
age groups: below and over 50 years of age. In the first
group, SVR was obtained in 83/133 cases (62.4%), and in
the other one in 16/37 (43.2%). The difference is statistical-
ly significant (p=0.04): a higher percentage of subjects
below 50 years of age benefited from the therapy.
The overall treatment efficacy assessed 6 months after its
completion reached 58.2% for all the patients without tak-
ing into consideration HCV genotypes and viremia levels.
Among patients with genotype 1, SVR was obtained in
75/142 (52.8%), and with non-1 – in 24/28 (85.7%), which
is a statistically significant difference (p=0.001). However,
such a difference was not observed in the comparison of
patients with baseline viremia equal to or lower than 800
thousand IU/ml (60/94, i.e. 63.8%) with those having
viremia levels above that value (39/76, i.e. 51.3%). In the
genotype 1 subgroup, a statistically significant difference
(p=0.028) between patients with high and low viremia
was demonstrated according to the criteria described
above (SVR – 26/62, i.e. 41.9% and 49/80, i.e. 61.3%,
respectively). Such a difference was not observed among
patients infected with non-1 genotype (SVR, 13/14 and
11/14, respectively).
No statistical significance was found in the presented
material on the comparison of SVR in groups previous-
ly treated and untreated with antiviral therapy (35/53,
i.e. 66% and 64/117, i.e. 54.7%, respectively, p>0.05).
No statistically significant differences (p>0.05) were
found in SVR analyzed according to fibrosis stage. The
highest rate of SVR (10/11) was obtained in patients
with 0 stage fibrosis, the lowest (5/11) in those with max-
imum, stage 4 fibrosis. Similar distribution of SVR fre-
quency was found in stage 1 (30/53, i.e. 56.6%), stage 2
(34/56, i.e. 60.7%) and stage 3 fibrosis groups (8/17).
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Figure 6. Mean values for neutrophils. Figure 7. Mean values for leukocytes.
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The patients receiving RBV doses higher than 10.6
mg/kg b.w. throughout the whole treatment period, sig-
nificantly more often (p=0.034) belonged to the group
of responders (48/71, i.e. 67.6%) as compared with those
receiving doses equal to, or lower than the above value
(42/84, i.e. 50%).
There were no differences (p>0.05) between patients
treated with PegIFNα-2a and RBV doses exceeding
80% of the scheduled dose (82/138, i.e. 59.4%) as com-
pared with those receiving the doses of any drug lower
than 80% (16/29, i.e. 55.2%). No such difference was
also demonstrated when PegIFNα-2a and RBV were
analyzed separately with the same dose threshold i.e.
above and below 80%. For the former drug exceeding
the 80% value, SVR was obtained in 14/27 (51.9%) vs.
84/140 (60.0%), and for the latter one, in 6/7 (85.7%) vs.
92/160 (57.5%), respectively. At this stage of analysis, in
view of the lack of complete data obtained immediately
after the completion of treatment, no analysis of results
aimed at the determination of ETR was performed.
DISCUSSION
Disappearance of HCV-RNA 6 months after completion
of the therapy (SVR) was found in 58.2% of patients. The
results are consistent with the range reported by interna-
tional studies using the same type of PegIFNα2a with
RBV (56–63%), and PegIFNα2b with RBV (54–61%),
irrespective of HCV genotype [4–6], also using dosage,
including that of RBV, adjusted to the patients’ body
weight. The predominance of men in our analysis is due
to the fact that there are more representatives of that sex
in the population of HCV-infected subjects and the crite-
ria of recruitment (non-random) did not include the sex
criterion. No statistically significant difference (p>0.05)
in the SVR rates between women (67.2%) and men
(53.6%) was demonstrated, although the percentages
indicate the predominance of female gender. This is in
agreement with data reported in the literature, according
to which differences in treatment response between the
sexes disappeared [5] when dosage of ribavirin per kg
b.w. was taken into account, while others [6] did not indi-
cate this difference at all. On the other hand, according
to other authors [4–6], SVR was significantly more fre-
quent (p<0.05) in patients below 50 years of age in com-
parison with those over that age limit, when such arbi-
trary division was applied (62.4% and 43.2%).
As presented in the results section, final analysis allowing
to assess SVR in subjects with known fibrosis stages (S)
was possible in 148 patients. In that group, extreme val-
ues, i.e. no fibrosis (S0) and the most advanced stage,
morphologically equivalent to cirrhosis (S4) were repre-
sented by the same numbers of patients (11 in each
group, i.e. 7.4%). Most patients were classified as S1 and
S2 (73.6%), but 17 (11.5%) as S3. This indicates a non-
homogeneous quantitative distribution of this character-
istics with the predominance of subjects with mild forms
of fibrosis. With high probability (low numbers of
patients in S1 and S4 subgroups), this was the reason for
obtaining no statistically significant differences in SVR
frequency related to the stage of fibrosis. The literature
data [4–6] indicate consistently that the lower the fibrosis
stage, the higher SVR rates are obtained. No fibrosis or
its mild form are mentioned as a positive prognostic fac-
tor. Some publications demonstrate that antiviral treat-
ment, even resulting in no HCV-RNA elimination, caus-
es inhibition or deceleration of both the inflammatory
process and fibrosis, as well as that SVR patients may
even demonstrate regression of previously existing cir-
rhosis [8]. Our study, for the reasons explained in the
results section, did not take into account the stage of the
inflammatory process. It will be included in a publication
concerning a larger number of treated patients. The
effect of the therapy on liver morphology parameters
also could not be assessed because no control liver biop-
sies were performed.
HCV genotype is one of the most important prognostic
factors in the treatment of chronic hepatitis C, because
the SVR rates obtained in genotype 1-infected patients
are always lower, irrespectively of PegIFNα type used
with RBV, than those obtained in non-1 genotype
patients. The above has been confirmed by our results:
52.8% and 85.7%, respectively (p<0.05). In both sub-
groups, the percentages are very slightly higher than the
corresponding literature data [4–6]: within the 42–52%
range for genotype 1 versus approximately 80% for non-
1. As serum HCV-RNA was not determined in a suffi-
cient number of patients immediately after treatment,
with a reservation made for the possibility to return to
this analysis in the subsequent publications, no immedi-
ate results of the end of treatment response (ETR) can
be assessed. The above also means that it is impossible to
calculate the frequency of relapses, i.e. transitions from
negative HCV-RNA on ETR assessment date to repeated
detection of HCV-RNA after six months from that date.
The frequency of this phenomenon may amount to over
ten per cent [5]. For the purpose of extended analysis,
HCV-RNA determination after 12 weeks of treatment,
not included in the study protocol, would also be very
useful. With high probability (only 1.6% chance of
obtaining SVR after continued treatment) the final out-
come can be predicted on the basis of the above determi-
nation at such an early stage of the therapy [9,10].
Statistically significant difference in SVR concerned the
patients infected with genotype 1 with viremia below 800
thousand IU/ml after division of the evaluated patients into
two subgroups, compared with the value higher than, or
equal to, the above threshold value (determinations per-
formed prior to the commencement of the therapy). On
the other hand, for all the treated patients and for those
with non-1 genotype no such differences were demonstrat-
ed. According to the literature data, higher viremia levels
resulted in a lower SVR frequency in patients infected with
genotype 1 [4,6], those with non-1 genotype [4], as well as
those without regard to genotype [4,5].
No statistical difference was demonstrated in the pre-
sented study with respect to the SVR rates obtained in
patients previously treated and untreated with antiviral
therapy. However, this conclusions is based on very
weak grounds, i.e. very general information available in
the database, resulting from the use of very simplified
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criteria: treated – untreated. The patients characteristics
did not include very important details such as time
elapsed from the completion of previous treatment until
the moment of inclusion in the analyzed study, the
duration and type of previous treatment: non-pegylated
IFNα monotherapy, or combined IFNα and RBV treat-
ment. Therefore, the results discussed here should be
interpreted very cautiously. Retreatment with non-
pegylated IFNα and RBV of the patients who were non-
-responders to prior IFNα monotherapy, results in SVR
rates no higher than 15% [11].
RBV, deposited in erytrocytes, causes generally mild
hemolytic anemia [5], reflected by statistically significant
decrease of Hb concentration, observed during the treat-
ment of the discussed patients. In some patients, tempo-
rary reduction of RBV doses was necessary for this rea-
son, but it did not lead to discontinuation of the therapy
in any case. As reported by another team [5] patients
who had received RBV doses above 10.6 mg/kg b.w.
responded to the treatment better (p=0.034) than those
treated with lower average doses (67.6% vs. 50%). As it
was presented in the study results, dosage over and
above 80% of the scheduled PegIFNα doses, both jointly
with RBV, and separately, for both these drugs, does not
demonstrate a statistically significant difference in SVR
rates. Maintaining dosage of the combined treatment at
a level greater than or equal to 80% increases its efficacy
[12]. In the patients we treated, for whom we had full
access to information, 29 of 167 patients (17.4%) rece-
ived doses of any medication below this level, which is a
relatively small proportion compared to those receiving
doses greater than 80%.
The decrease of leukocyte, granulocyte and platelet
counts is a result of moderate toxic effect of IFNα and
Peg-IFNα on the bone marrow. Reduction of doses,
usually temporary, allows to continue the therapy. The
treatment was discontinued in 2 patients (week 40 and
41) because of persistent neutropenia (fall to the values
of 410 and 680/mm3). Persistent thrombocytopenia (the
lowest value of 32 thousand/mm3) was the reason for
such decision in 1 patient (in week 30). Other authors
discontinued treatment for that reason with similar fre-
quency [5]. Decreased AlAT activity, as commonly inter-
preted in the literature, is associated with inflammation
intensity decreased as a result of antiviral treatment.
The reasons for discontinuation of treatment in 9
patients (4.7%) in addition to the three mentioned above
(thrombocytopenia and neutropenia) included, in three
other cases: suspected carcinoma follicularis (week 42),
hyperthyroidism (week 22), general poor tolerance with
recurrent syncopes (week 30). Other 3 patients (weeks:
2, 20 i 29) withdrew from the treatment program despite
the lack of any objective reasons. Other symptoms occur-
ring in the course of treatment, which did not lead to its
discontinuation, are discussed in a separate publication.
CONCLUSIONS
1. The overall treatment efficacy assessed 6 months after
its completion reached 58.2% for all the patients with-
out taking into consideration HCV genotypes and
viremia levels.
2. Patients infected with non-1 genotype responded to
the treatment significantly better than those with
genotype 1 (85.7% vs. 52.8%).
3. Patients infected with genotype 1 with low viremia
levels responded significantly better than those with
genotype 1 and high viremia (61.3% vs. 41.9%).
4. The response to treatment was significantly better in
patients below 50 years of life.
5. No significant differences in response were found
with respect to: sex, previous antiviral treatment and
the stage of fibrosis.
6. Patients treated with ribavirin doses ≥10.6 mg/kg
responded significantly better than those treated with
doses <10.6 mg/kg, reflecting the importance of dos-
ing ribavirin by body weight in patients infected with
genotype 1.
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